FDA. Title 21 Code of Federal Regulations (CFR) 320.24. https://www.ecfr.gov/current/title-21/section-320.24. Accessed 22 Dec 2023.
Ring A, Lang B, Kazaroho C, Labes D, Schall R, Schütz H. Sample size determination in bioequivalence studies using statistical assurance. Br J Clin Pharmacol. 2019;85(10):2369–77.
Article CAS PubMed PubMed Central Google Scholar
Li S. Pharmacodynamic bioequivalence testing. J Clin Pharm Ther. 2012;37(5):497–8.
Article CAS PubMed Google Scholar
Xu SM, Xu YY, Yan J, Zhang YF, Li D, Li D, et al. Method for evaluating the human bioequivalence of acarbose based on pharmacodynamic parameters. J Int Med Res. 2020;48(10):300060520960317.
Article CAS PubMed Google Scholar
FDA. Guidance for Industry: Bioequivalence Guidance. https://www.fda.gov/media/70115/download. Accessed 26 Dec 2023.
FDA. Guidance on Acarbose. https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020482.pdf. Accessed 24 Mar 2024.
Chen Y, Guo F, Wang X, Liu L, Yang C, Xiong Y, et al. Evaluation of the bioequivalence of Acarbose in Healthy Chinese people. Clin Pharmacol Drug Dev. 2021;10(10):1225–30.
Article CAS PubMed PubMed Central Google Scholar
Seng Yue C, Ozdin D, Selber-Hnatiw S, Ducharme MP. Opportunities and challenges related to the implementation of model-based bioequivalence criteria. Clin Pharmacol Ther. 2019;105(2):350–62.
FDA. Draft Guidance on Orlistat. https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020766.pdf. Accessed 28 Mar 2024.
Zeng Y, Singh S, Wang K, Ahrens RC. Effect of Study Design on Sample size in studies intended to Evaluate Bioequivalence of Inhaled Short-Acting β-Agonist formulations. J Clin Pharmacol. 2018;58(4):457–65.
Article CAS PubMed Google Scholar
FDA. Draft Guidance on Albuterol Sulfate. https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020503.pdf. Accessed 2 Mar 2024.
Zaid AN, Zohud N, E’Layan B, Aburadi T, Jaradat N, Ali I, et al. Pharmacodynamic testing and new validated HPLC method to assess the interchangeability between multi-source orlistat capsules. Drug Des Devel Ther. 2017;11:3291–8.
Article CAS PubMed PubMed Central Google Scholar
Johnson S, Schwartz SM. Pharmacologic and pharmacodynamic equivalence of 2 formulations of Orlistat. Clin Pharmacol Drug Dev. 2018;7(7):773–80.
Article CAS PubMed Google Scholar
FDA. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. https://www.fda.gov/media/163638/download. Accessed 2 Mar 2024.
Kang H. Sample size determination and power analysis using the G*Power software. J Educ Eval Health Prof. 2021;18:17.
Article PubMed PubMed Central Google Scholar
Hauschke D, Steinijans VW, Diletti E, Burke M. Sample size determination for bioequivalence assessment using a multiplicative model. J Pharmacokinet Biopharm. 1992;20(5):557–61.
Article CAS PubMed Google Scholar
Kang D, Schwartz JB, Verotta D. A sample size computation method for non-linear mixed effects models with applications to pharmacokinetics models. Stat Med. 2004;23(16):2551–66.
Tang BH, Yao BF, van den Anker J, Zhao W. Optimal sample size for use in neonatal pharmacokinetic studies. Ther Innov Regul Sci. 2022;56(3):517–22.
Ogungbenro K, Aarons L. How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach. Eur J Clin Pharmacol. 2008;64(7):705–13.
Vong C, Bergstrand M, Nyberg J, Karlsson MO. Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models. AAPS J. 2012;14(2):176–86.
Article PubMed PubMed Central Google Scholar
Nakamura T, Takeuchi T. Pancreatic steatorrhea, malabsorption, and nutrition biochemistry: a comparison of Japanese, European, and American patients with chronic pancreatitis. Pancreas. 1997;14(4):323–33.
Article CAS PubMed Google Scholar
Pannu PK, Calton EK, Soares MJ. Calcium and Vitamin D in obesity and related chronic disease. Adv Food Nutr Res. 2016;77:57–100.
Comments (0)